Skip to main content

Advertisement

Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study

Article metrics

  • 506 Accesses

The original article was published in Arthritis Research & Therapy 2019 21:91

Correction to: Arthritis Res Ther

https://doi.org/10.1186/s13075-019-1880-4

Following publication of the original article [1], the authors noticed that two corrections were not implemented during the production process. The original article [1] has been corrected.

In Fig. 1b, the heading should read: Adjusted survival due to lack of effectiveness

In Fig. 2b, the heading should read: Adjusted survival due to toxic adverse events

In addition, the authors would like to update the legends of Figure 1, 2, 3 and 4 to the following:

Fig. 1 Drug survival rates due to lack of effectiveness in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 2 Drug survival rates due to toxic adverse events in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 3 Drug survival rates due to remission in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 4 Overall drug survival rates (excluding non-toxic reasons and remission) in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

The publishers apologise for the errors. The corrected figures are given below:

Fig. 1
figure1

Drug survival rates due to lack of effectiveness in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Fig. 2
figure2

Drug survival rates due to toxic adverse events in a non-adjusted cases and b adjusted cases. Adjusted confounders were baseline sex, age, disease duration, concomitant prednisolone and methotrexate, and number of previously used bDMARDs. ABT = abatacept, ADA = adalimumab, CZP = certolizumab pegol, ETN = etanercept, GLM = golimumab, IFX = infliximab, TCZ = tocilizumab, bDMARDs = biological disease-modifying antirheumatic drugs

Reference

  1. 1.

    Ebina, et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study. Arthritis Res Ther. 2019;21:91 https://doi.org/10.1186/s13075-019-1880-4.

Download references

Author information

Correspondence to Kosuke Ebina.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark